A kind of multifunctional fusion polypeptide and its preparation method and application

A fusion polypeptide, multi-functional technology, applied in the preparation method of peptide, fusion polypeptide, hybrid peptide and other directions, can solve the problems of single target, easy to produce drug resistance, lack of specific drugs for the treatment of pulmonary fibrosis, etc. The method is simple, the effect of increasing the activity of anti-pulmonary fibrosis and anti-pulmonary infection, and good application prospect

Active Publication Date: 2021-05-07
NANJING ANJI BIOLOGICAL TECH CO LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Aiming at the problems of existing polypeptide drugs such as single target, easy drug resistance, and lack of specific drugs for the treatment of pulmonary fibrosis, the present invention provides a multifunctional fusion polypeptide and its preparation method and application, which can treat human pulmonary fibrosis , lung tissue lesions, lung cancer and other tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of multifunctional fusion polypeptide and its preparation method and application
  • A kind of multifunctional fusion polypeptide and its preparation method and application
  • A kind of multifunctional fusion polypeptide and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Preparation and inspection of the multifunctional polypeptide of the present invention

[0043] In this example, polypeptides I-VI were all synthesized by solid-phase synthesis, separated and purified by preparative HPLC, and the purity of the polypeptide was determined by analytical high-performance liquid chromatography.

[0044] Polypeptide I-VI solid-phase synthesis method uses solid-phase carrier Fmoc-wang-resin (Gill Biochemical Co., Ltd.) as the starting material, and then uses protected amino acids to inoculate dipeptide to nonacupeptide in sequence, and fully washes the peptide after the work is completed. , Peptide cutting, and post-treatment to obtain the crude product of the polypeptide; dissolve the crude product, purify twice with preparative high-performance liquid phase, concentrate and freeze-dry to obtain the pure product, and finally obtain the refined product of the polypeptide through the third purification. The method can not only ensure the synthe...

Embodiment 2

[0073] In this example, polypeptides I-VI were all synthesized by liquid phase synthesis, separated and purified by preparative HPLC, and the purity of the polypeptide was determined by analytical high performance liquid chromatography. The following are the synthesis steps of polypeptide I, and the synthesis steps of polypeptide II-VI are the same as those of polypeptide I.

[0074] Polypeptide I synthesis steps are as follows:

[0075] 1. According to the sequence of polypeptide I, in 10 mL of dichloromethane, 1 mg of the first amino acid Pro and 1 mg of the second amino acid D-Pyr are connected through an amide bond, and the inactive groups of the amino acids participating in the reaction are modified with Fmoc.

[0076] 2. Add 10 mL of ammonia water to the above reaction system to remove the Fmoc group.

[0077] 3. Repeat the reaction of the first step, add the third amino acid D-Cys according to the sequence of the synthesized polypeptide, and modify the inactive group o...

Embodiment 3

[0081] Establishment of In Vitro Pulmonary Fibrosis Model

[0082] Human non-small cell lung cancer cell A549 was cultured in DMEM medium containing 10% (volume fraction) fetal bovine serum, cultured in a 5% carbon dioxide incubator at 37°C, and the medium was changed every other day, depending on the cell density. Take A549 cells in the logarithmic growth phase, digest with 0.25% trypsin to make cell suspension, adjust the cell concentration to 1×10 9 pcs / L, and according to 4×10 5 piece / cm 2 Density seeded at 90cm 2 In the cell culture dish, they were randomly divided into two groups: (1) control group: cultured with DMEM containing 10% (volume fraction) fetal bovine serum; (2) model group: containing 10% (volume fraction) fetal bovine serum, DMEM culture of transforming growth factor (TGF-β1, final concentration 5 μg / L). Place them in an incubator at 37°C with a volume fraction of 5% carbon dioxide, change the medium every other day, and passage as scheduled depending o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a multifunctional fusion polypeptide and its preparation method and application, belonging to the field of biopharmaceuticals. The fusion polypeptide of the present invention contains domains Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu, Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val- Pro, Arg‑Gly‑Asp and Gly‑Gly‑Gly‑Gly can treat human pulmonary fibrosis, lung tissue lesions, lung cancer and other tumors, and in the pulmonary fibrosis cell model, the polypeptide of the present invention can significantly reduce the The content of hydroxyproline in the cells can inhibit the progress of pulmonary fibrosis; MTT experiments show that the polypeptide of the present invention can inhibit the proliferation of various human tumor cells; the polypeptide of the present invention is prepared by artificial synthesis, and the preparation method is simple and has Good application prospects.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and more specifically relates to a new multifunctional fusion polypeptide and its preparation method and application. Background technique [0002] Pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF) has long been considered as a progressive and basically irreversible pathological change. The 5-year mortality rate of IPF patients reaches 65% after diagnosis, which is a serious threat. public health. Due to the minimal efficacy of current treatment measures, IPF has not even formed a recognized treatment plan. The most common symptom of pulmonary fibrosis is: difficulty breathing. In mild pulmonary fibrosis, dyspnea often occurs with strenuous activity and is therefore often overlooked or misdiagnosed as another disorder. When pulmonary fibrosis progresses, dyspnea also occurs at rest, and patients with severe pulmonary fibrosis may develop progressive dyspnea. [0003] A varie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C07K5/09C07K7/06C07K1/02C07K1/06A61K38/16A61P11/00A61P31/00A61P35/00
CPCC07K5/0817C07K7/06A61K38/00C07K2319/01A61K38/16C07K1/02C07K1/04C07K1/06C07K14/00C07K19/00A61P11/00A61P35/00C07K14/8146C07K2319/00
Inventor 徐寒梅
Owner NANJING ANJI BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap